Abstracts Archive - Page 419 of 2607 - ACR Meeting Abstracts

Abstract Number: 1734 • ACR Convergence 2023
Serum PDGF-BB Levels Correlate with Lung Fibrosis in Mice Injected with Malondialdehyde-Acetaldehyde and/or Citrulline Modified Vimentin
Nozima Aripova¹, Michael Duryee¹, Carlos Hunter¹, Amy Nelson¹, Breanna Butler¹, Jill Poole¹, Bryant England¹, Geoffrey Thiele¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA), such as interstitial lung disease (RA-ILD), are a major contributor to morbidity and mortality. The mechanism of pulmonary…
Abstract Number: 1852 • ACR Convergence 2023
Human Papillomavirus Vaccine Uptakes in Ethnically Diverse Women Living with Systemic Lupus Erythematosus
Sebastian Bruera¹, Yinan Huang², Savannah Bowman¹, Maria Suarez-Almazor³, Grace Lo¹, Maria A. Lopez-Olivo⁴ and Sandeep Agarwal¹, ¹Baylor College of Medicine, Houston, TX, ²Department of Pharmacy Administration, University of Mississippi School of Pharmacy, Oxford, MS, ³MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Women with systemic lupus erythematosus are at an increased risk of infections from the human papillomavirus (HPV) and subsequently HPV-mediated malignancies and genital warts.…
Abstract Number: 1850 • ACR Convergence 2023
Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data
Andriko Palmowski¹, Eric Roberts², Jing Li², Emma Kersey², Rachael Stovall², Frank Buttgereit³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of California San Francisco, San Francisco, CA, ³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ⁴University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: According to recent ACR and EULAR rheumatoid arthritis (RA) guidelines, glucocorticoids (GCs) should only be used for brief periods or not at all. Our…
Abstract Number: 1741 • ACR Convergence 2023
The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis
Sara Turcinov¹, Charlotte de Vries², Ravi Kumar Sharma², Christina Gerstner², Bruno Raposo², Anatoly Dubnovitsky², William Kwok³, Karine Chemin², Vivianne Malmström⁴ and Aase Hensvold⁵, ¹Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet. Theme of Inflammation and Ageing, Medical Unit Gastro, Derma, Rheuma, Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet. Center for Rheumatology, Academic Specialist Center, Stockholm, Sweden
Background/Purpose: CD4+ T cells recognizing citrullinated epitopes are present in peripheral blood of anti-citrulline protein antibody (ACPA) positive rheumatoid arthritis (RA) patients at time of…
Abstract Number: 1854 • ACR Convergence 2023
What Is Our Regional Delay to Diagnosis in Patients with Axial Spondyloarthropathy – Are We Hitting the Target? Data from a Multi-centre UK Patient Cohort
Gurdeep Dulay¹, Antoni Chan², Catherine Boys³, Aisling Coy⁴, Mary Devin⁵, Leslie Goh⁶, Arran McDougall², Kathryn Rigler², Jacqui Tomkins⁷, Dinny Wallis⁷ and Emma Williams⁸, ¹Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ²Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, ³NHS, Basingstoke, United Kingdom, ⁴Salisbury NHS Foundation Trust, Salisbury, United Kingdom, ⁵Dorset County Hospital NHS, Dorchester, United Kingdom, ⁶NHS, Portsmouth, United Kingdom, ⁷NHS, Southampton, United Kingdom, ⁸NHS, Winchester, United Kingdom
Background/Purpose: Due to the insidious onset of axial spondyloarthritis (AxSpA), there is often a significant delay to diagnosis. The average delay to diagnosis in the…
Abstract Number: 1757 • ACR Convergence 2023
Quantitative Assessment of Synovial Vascularity Using Power Doppler Index in Rheumatoid Arthritis and Psoriatic Arthritis Patients with High Disease Activity
Michał Jakubaszek, Maria Maślińska and Brygida Kwiatkowska, National Institute of Geriatrics Rheumatology and Rehabilitation, Warsaw, Poland
Background/Purpose: Usefulness of quantitative assessment of synovial vascularity in ultrasound (US) imaging in patients with active RA and PsA (peripheral arthritis). Additionally the assessment of…
Abstract Number: 1751 • ACR Convergence 2023
Profiling of Anti-PAD IgG and IgA in Patients from the Head-to-head Adalimumab vs Abatacept Rheumatoid Arthritis AMPLE Trial and Matched Healthy Controls
Namit Kumar¹, Xueer Chen², Mary Ann Aure³, Andy Ishii⁴, Laura Martinez-Prat⁵, chelsea Bentow⁴, Jasmine Saini², Michael Mahler⁴ and Laurence Menard², ¹Bristol Myers Squibb, San Diego, CA, ²Bristol Myers Squibb, Princeton, NJ, ³Werfen, Chula Vista, CA, ⁴Werfen, San Diego, CA, ⁵Werfen Autoimmunity, Sant Cugat del Vallès, Spain
Background/Purpose: A hallmark of rheumatoid arthritis (RA) is the presence of anti-citrullinated protein antibodies (ACPA) targeting neoantigens which are generated by a family of enzymes…
Abstract Number: 1849 • ACR Convergence 2023
Impact of the First Three Waves of the Covid-19 Pandemic on Everyday Restrictions and Clinical Care of Patients with Spondyloarthritis Across Europe – Results from the EuroSpA Collaboration
Brigitte Michelsen¹, Bente Glintborg², Kim Lauper³, Bjorn Gudbjornsson⁴, Lykke Ørnbjerg⁵, Gerdur Maria Gröndal⁶, Karin Laas⁷, Sigrid Vorobjov⁸, Dan Nordstrom⁹, Heikki Relas⁹, Adrian Ciurea¹⁰, Burkhard Moeller¹¹, Isabel Castrejon¹², Lucia Otero-Valera¹³, Ziga Rotar¹⁴, Katja Perdan Pirkmajer¹⁵, Anne Gitte Loft¹⁶, Jakub Zavada¹⁷, Karel Pavelka¹⁸, Eirik Kristianslund¹⁹, Tore Kvien²⁰, Marleen van de Sande²¹, Pasoon Hellamand²², Florenzo Iannone²³, Roberto F. Caporali²⁴, Ana Maria Rodrigues²⁵, Maria Jose Santos²⁶, Catalin Codreanu²⁷, Corina Mogosan²⁸, Merete Hetland⁵ and Mikkel Østergaard²⁹, ¹Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ²Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ³Geneva University Hospitals, Genève, Switzerland, ⁴Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁵Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁶Landspitali University Hospital; University of Iceland, Reykjavik, Iceland, ⁷Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ⁸National Institute for Health Development, Tallinn, Estonia, ⁹Helsinki University Hospital, Helsinki, Finland, ¹⁰University Hospital Zurich, Zürich, Switzerland, ¹¹Inselspital - University Hospital Bern, Bern, Switzerland, ¹²Hospital Universitario Gregorio Marañón, Madrid, Spain, ¹³Spanish Society of Rheumatology, Madrid, Spain, ¹⁴University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁵University Medical Centre Ljubljana; University of Ljubljana, Ljubljana, Slovenia, ¹⁶Aarhus University, Horsens, Denmark, ¹⁷Institute of Rheumatology; Charles University, Prague, Czech Republic, ¹⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ¹⁹Diakonhjemmet Hospital, Oslo, Norway, ²⁰Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²¹Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²²Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ²⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ²⁵Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ²⁶Hospital Garcia de Orta, Almada, Lisboa, Portugal, ²⁷Center for Rheumatic Diseases, Bucharest, Romania, ²⁸University of Medicine and Pharmacy, Bucharest, Romania, ²⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: The Covid-19 pandemic constituted major challenges for health-care services worldwide. We aimed to compare Covid-19 restrictions across Europe during the first three waves of…
Abstract Number: 1853 • ACR Convergence 2023
Each Joint in a 28 Joint Count Is More Likely to Be Affected by Deformity/Limited Motion Than by Swelling in Rheumatoid Arthritis Patients with Long Disease Duration: Deformity/Limited Motion Should Be Included in Joint Counts Performed in Routine Care
Rahel Hunter¹, Nicholas Rodwell² and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Liverpool, Australia
Background/Purpose: The 28 joint count for rheumatoid arthritis (RA) was designed to recognize 3 abnormalities: swelling, (SWL), tenderness/pain on motion (TEN), and deformity/limited motion (DEF),…
Abstract Number: 1743 • ACR Convergence 2023
Individuals At-risk for and with Rheumatoid Arthritis Have Elevated Fecal Concentrations of Arthritogenic Subdoligranulum didolesgii Correlating with CCP3 Antibodies
Lyndsey Cole¹, Sucai Liu², Brendan Allen², Marie Feser³, Kristen Demoruelle³, kevin Deane³, Michael Holer³ and kristine Kuhn², ¹University of Colorado School of Medicine, Centennial, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Our prior investigation identified a specific strain of Subdoligranulum didolesgii, S. dido7, to which dual IgA/IgG family plasmablast-derived monoclonal autoantibodies from individuals at-risk for…
Abstract Number: 1690 • ACR Convergence 2023
Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients with Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
Mikkel Østergaard¹, Walter P. Maksymowych², Mikael Boesen³, Robert Lambert⁴, Guillermo Valenzuela⁵, Michael Bubb⁶, Olga Kubassova⁷, Jyotsna Reddy⁸, Stephen Colgan⁹, Yuri Klyachkin¹⁰, Cynthia Deignan¹¹, Lihua Tang⁸, Maria Paris⁸ and Philip J. Mease¹², ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ²University of Alberta, Edmonton, AB, Canada, ³Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, ⁴Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶University of Florida, Gainesville, FL, ⁷Image Analysis Group, Philadelphia, PA, ⁸Amgen, Inc., Thousand Oaks, CA, ⁹Amgen, Inc., Halton Hills, ON, Canada, ¹⁰Amgen, Inc., Lexington, KY, ¹¹Amgen, Inc., Agoura Hills, CA, ¹²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: PsA is characterized by inflammatory arthritis, enthesitis, dactylitis, and spondylitis. Apremilast (APR) is an oral immunomodulating phosphodiesterase-4 inhibitor approved for the treatment of PsA.…
Abstract Number: 1695 • ACR Convergence 2023
Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis
Philip Carlucci¹, Jasmine Shwetar², Siddarth Gurajala³, Qian Xiao³, Joseph Mears⁴, Katie Preisinger¹, Devyn Zaminski⁵, Kristina Deonaraine¹, Peter Izmirly¹, Andrea Fava⁶, Judith James⁷, Joel Guthridge⁷, Brad Rovin⁸, Sethu Madhavan⁸, Wade DeJager⁷, David Wofsy⁹, Ming Wu², Chaim Putterman¹⁰, Deepak Rao¹¹, Betty Diamond¹², Derek Fine¹³, Jose Monroy-Trujillo¹³, Kristin Haag¹⁴, H Michael Belmont⁵, William Apruzzese¹¹, Anne Davidson¹², Fernanda Payan-Schober¹⁵, Richard Furie¹⁶, Paul Hoover¹¹, Celine Berthier¹⁷, Maria Dall'Era⁹, Kerry Cho¹⁸, Diane L. Kamen¹⁹, Kenneth Kalunian²⁰, Jennifer Anolik²¹, Arnon Arazi²², Soumya Raychaudhuri¹¹, Nir Hacohen²³, Michelle Petri²⁴, Robert Clancy²⁵, Kelly Ruggles², Jill Buyon²⁵ and The Accelerating Medicines Partnership in RA/SLE²⁶, ¹New York University School of Medicine, New York, NY, ²NYU Langone, New York, NY, ³Harvard Medical School, Boston, MA, ⁴Michigan University, Ann Arbor, MI, ⁵NYU School of Medicine, New York, NY, ⁶Johns Hopkins University, Baltimore, MD, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Ohio State University, Columbus, OH, ⁹University of California San Francisco, San Francisco, CA, ¹⁰Albert Einstein College of Medicine, Bronx, NY, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Johns Hopkins School of Medicine, Baltimore, MD, ¹⁴Thomas Jefferson University, Philadelphia, PA, ¹⁵Texas Tech University Health Sciences Center, El Paso, TX, ¹⁶Northwell Health, Manhasset, NY, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸UCSF Health, San Francisco, CA, ¹⁹Medical University of South Carolina, Charleston, SC, ²⁰University of California San Diego, La Jolla, CA, ²¹University of Rochester Medical Center, Rochester, NY, ²²Broad Institute of MIT and Harvard, Melrose, MA, ²³Broad Institute of MIT and Harvard, Cambridge, MA, ²⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁵NYU Grossman School of Medicine, New York, NY, ²⁶Multiple, Bethesda, MD
Background/Purpose: The G1 and G2 risk variants (RVs) in Apolipoprotein L1 (APOL1) associate with CKD and may contribute to poorer outcomes for African American (AA)…
Abstract Number: 1705 • ACR Convergence 2023
Reduced DNASE1L3 Activity and Increased Anti-NET Protective Antibodies Contributes to Accumulation of Neutrophil Extracellular Traps in Pediatric SLE Patients
Betsy Barnes¹, Lydia Thomas², Jenna Battaglia Battaglia³, Kim Simpfendorfer³, Joyce Hui-Yuen⁴, Vinay Sharma⁵ and Bharati Matta⁶, ¹Northwell Health, Manhasset, NY, ²Northwell Health - Cohen Children's Medical Center, Lake Success, NY, ³Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁴North Shore LIJ Health System, Great Neck, NY, ⁵Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India, ⁶The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY and Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, NY
Background/Purpose: Pediatric systemic lupus erythematosus (pSLE) is a multisystemic chronic autoimmune disease with high renal involvement. In SLE, neutrophil extracellular traps (NETs) are considered a…
Abstract Number: 1310 • ACR Convergence 2023
Comparison of Two Methotrexate Initiation Strategies in Rheumatoid Arthritis in Current Practice
Paola Vidal-Montal¹, Alice Combier², Alexia STEELANDT², Marion THOMAS², Javier Narvaez³, Joan Miquel Nolla¹, Yannick ALLANORE⁴ and Jerome AVOUAC⁵, ¹Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Université Paris Cité, Paris, France, ⁵Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: To compare the efficacy and tolerance at 3 and 6 months of two methotrexate (MTX) initiation strategies in rheumatoid arthritis (RA). Methods: Retrospective,monocentric,cross-sectionalstudy including…
Abstract Number: 1322 • ACR Convergence 2023
Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
Christoph Burkart, Clara Polizzi, Lisa Eide, Max Pastenes, David Siefker and Leslie Nangle, aTyr Pharma, San Diego, CA
Background/Purpose: Efzofitimod, a novel immunomodulator, has shown clinical proof-of-concept in a Phase 1b/2a clinical trial in patients with pulmonary sarcoidosis and is currently enrolling a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].